GLP-1 Weight-Loss Drugs Face Growing Scrutiny After Inquest Deaths
Published on 08/31/2026 at 10:37 | Editorial boerse-global.de
UK employers and health professionals are being urged to take note of mounting safety concerns around GLP-1 receptor agonist medications, as coroners, regulators and medical experts call for tighter controls on how drugs such as semaglutide and tirzepatide are prescribed and monitored.
Inquests Raise Questions Over Patient Safety
Recent legal proceedings have examined the deaths of patients using tirzepatide-based weight-loss medications, with coroners highlighting gaps in care. In one case, 73-year-old Caroline Savage died in October 2024 from fecal peritonitis following a bowel perforation. She had been taking Mounjaro for four months to treat lipedema, and coroner Yvonne Blake indicated that a prevention of future deaths report would be issued, noting communication gaps during the patient's care.
A separate inquiry examined the death of Josephine Nasr, a 19-year-old London law student. Nasr, who was classified as overweight but not obese, died of a cardiac arrhythmia linked to an undiagnosed congenital myocardial bridge and an electrolyte imbalance after using the weight-loss drug Zepbound, which had been prescribed in California.
These cases have sharpened concerns about the physical toll of rapid weight loss and the importance of thorough medical screening before these drugs are administered.
Concerns Over "Cosmetic" Use and Telehealth Gaps
Medical experts are increasingly worried about the use of GLP-1 medications for "cosmetic" weight reduction by individuals who do not meet clinical obesity criteria. An editorial in the journal Diabetology International highlighted the dangers of inappropriate use, citing cases in Japan where three women aged between 21 and 23 were hospitalised with ketoacidosis. Two of the women were not obese, and one had been following a restricted carbohydrate diet while using tirzepatide.
The role of telehealth in distributing these drugs has also come under fire. In Australia, a woman with a history of anorexia was reportedly prescribed a GLP-1 medication via a telehealth platform that failed to conduct an eating disorder screening. Dr. Monique Ryan has requested an inquiry into telehealth prescribing practices, noting that national standards for such services are not expected until late 2027.
These cases underscore how gaps in screening and monitoring can have serious consequences — a lesson that applies just as much to workplace safety as to clinical care. UK employers have their own legal duties to identify and control risks before they cause harm, and failing to document those assessments can leave them exposed. A free toolkit provides ready-to-use risk assessments and checklists that help you meet your obligations under the Health & Safety at Work Act 1974. Download the free Health & Safety Toolkit
Muscle Loss, Weight Regain and Other Side Effects
As the market for weight-loss injections expands, clinicians are detailing the physical consequences of treatment. Clinical dietitians have observed that GLP-1 injections can lead to significant muscle loss, estimated at approximately 3.5kg for every 10kg of total weight lost.
Research also suggests that patients may regain roughly two-thirds of their lost weight within a year of discontinuing the medication, potentially necessitating lifelong use.
Regulators are evaluating further safety signals. A study published in the BMJ indicated that GLP-1 drugs are associated with a 37% higher risk of alopecia compared to SGLT-2 inhibitors, and a 68% higher risk compared to DPP-4 inhibitors. The U.S. Food and Drug Administration (FDA) is currently assessing these findings.
Medical professionals have also warned that vaping while taking these medications can exacerbate gastrointestinal side effects, such as acid reflux and nausea, and increase the risk of dehydration.
Misuse on the Rise and a Growing Black Market
Data from poison control centres and border authorities reflects the scale of misuse. In the United States, calls to poison control regarding GLP-1 receptor agonists have nearly doubled since the FDA approved the drugs for weight loss in 2021. Common errors include patients taking the medication daily instead of weekly, or starting treatment at the highest available dose.
A University of Louisville study found that approximately one-third of individuals with eating disorders reported lifetime use of GLP-1 medications, with some admitting to sharing prescriptions or taking unprescribed doses.
Beyond clinical misuse, a significant black market has emerged. Brazilian authorities reported seizing more than 76,000 pens and vials of semaglutide and tirzepatide at the Brazil-Paraguay border during the first half of 2026 — nearly triple the total amount seized during the entirety of the previous year. The figures highlight the growing global challenge of unregulated drug distribution.
